Circulation of Fluconazole-Resistant C. albicans. C. auris and C. 1 parapsilosis Bloodstream Isolates Carrying Y132F, K143R or 2 **T220L Erg11p Substitutions in Colombia.** 3 Andres Ceballos-Garzon a, b*, Ana Peñuela a, c*, Sandra Valderrama-Beltrán d, Yerly Vargas-4 5 Casanova a, Beatriz Ariza c, Claudia M. Parra-Giraldo a, e. 6 ^aUnidad de Proteomica y Micosis Humanas, Grupo de Investigación en Enfermedades 7 Infecciosas, Departamento de Microbiología, Pontificia Universidad Javeriana, Bogotá, 8 Colombia. c-ceballos@javeriana.edu.co (A.C-G.); 9 ^bUniversité Clermont Auvergne, INRAE, MEDiS, 63000 Clermont-Ferrand, France. 10 ^cLaboratorio clínico, Área de Microbiología, Hospital Universitario San Ignacio, Bogotá D.C, 11 Colombia. 12 ^dUnidad de Infectología, Departamento de Medicina Interna, Facultad de Medicina, Hospital 13 Universitario San Ignacio, Pontificia Universidad Javeriana. Bogotá D.C, Colombia. 14 ^eDepartamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad 15 Complutense de Madrid, Madrid, Spain. 16 §Corresponding author at: Unidad de Proteomica y Micosis Humanas, Grupo de Investigación 17 de Enfermedades Infecciosas, Departamento de Microbiologia, Pontificia Universidad 18 Javeriana, Bogotá, Colombia Carrera 7 # 43-82 Lab 404 Edificio 52, Bogotá, Colombia. E-19 mail address: claudia.parra@javeriana.edu.co (CP-G). 20 *These authors contributed equally to this work 21 22 23 24 25 26

Abstract

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

Colombia.

Although Candida spp., is a common cause of bloodstream infections and is often associated with high mortality rates, its resistance to antifungal drugs, and the molecular mechanisms involved have been poorly studied in Colombia. Here, 123 bloodstream isolates of Candida spp. were collected. MALDI-TOF MS identification and fluconazole (FLC) susceptibility patterns were assessed on all isolates. Subsequently, sequencing of ERG11, TAC1 or MRR1, and efflux pumps were performed for resistant isolates. Out of 123 clinical strains, C. albicans accounted for 37.4%, followed by C. tropicalis 26.8%, C. parapsilosis 19.5%, C. auris 8.1%, C. glabrata 4.1%, C. krusei 2.4% and C. lusitaniae 1.6%. Resistance to FLC reached 18%. Erg11 amino acid substitutions associated with FLC-resistance (Y132F, K143R or T220L) were found in 58% of 19 FLC-resistant isolates. Furthermore, novel mutations were found in all genes studied. Regarding efflux pumps, 42% of 19 FLC-resistant Candida spp strains showed significant efflux activity. Finally, six of the 19 FLC-resistant isolates neither harbored resistance-associated mutations nor showed efflux pump activity. Although C. albicans remain the most predominant species, non-C. albicans species comprise a high proportion (62.6%). Among FLC-resistant species, C. auris (70%) and C. parapsilosis (25%) displayed the highest percentages of resistance. In 68% of FLC-resistant isolates, a mechanism that could explain their phenotype was found (e.g. mutations, flux pump activity or both). We provide evidence that endemic isolates harbor amino acid substitutions related with resistance to one of the most used molecules in the hospital setting, with Y132F being the most frequently detected one. **Key words:**

Candida species, bloodstream infections, fluconazole resistance, ERG11, Y132F,

Introduction

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

Invasive fungal infections (IFIs) due to Candida species are a frequent and life-threatening condition in hospital settings worldwide, and are often associated with high morbidity and mortality [1]. Candida albicans is the most isolated species, with close to a 30% mortality rate in candidemia [2]. However, non-albicans Candida species (NACS) such as C. glabrata and C. parapsilosis have emerged as a common cause, becoming the second or third most frequent species depending on geography, patient underlying condition, and age. For these species, the associated mortality rate is about 50% and 28%, respectively [3,4]. Another important NACS causing candidemia is C. auris, whose mortality rate ranges from 40% to 60% according to some studies, despite the fact its prevalence is unclear [5]. While current therapeutic options for IFIs are limited to only three classes of drugs (i.e., polyenes, azoles and echinocandins), the emergence of resistant strains to some of these molecules is even more concerning. For decades, azoles have been the most frequently used antifungal for treating Candida infections [6,7]. Although treatment with azoles can be effective, long-term use of fluconazole (FLC) has led to the emergence of *Candida* strains with decreased susceptibility. In the case of Candida spp, the molecular mechanisms behind FLC-resistance have been relatively well characterized [8,9]. Unlike C. auris which is often resistant to FLC, C. albicans and C. parapsilosis isolates were thought to be universally susceptible to FLC, but recent studies show an increased resistance. For example, a multicenter laboratory-based survey of candidemia conducted in South Africa indicates that more than half of *C. parapsilosis* isolates 62% (332/531) are resistant to FLC [10]. In addition, studies in Brazil, India, Kuwait, South Korea, Spain, Turkey, and the United States, as well as a recent global study, confirmed the emergence of FLC-resistance in C. parapsilosis [11–15]. Regarding C. albicans, this species exhibits lower levels of azole

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

resistance. However, resistant isolates have been reported from many countries around the world, including Colombia [16–18]. The main FLC-resistance mechanisms are associated with i) up-regulation of drug transporters, ii) alteration or up-regulation of the gene encoding the enzyme being targeted, which decreases binding affinity for the drug and increases concentration of the enzyme target, iii) alterations in the ergosterol synthetic pathway and iv) activation of pathways involved in the stress response, such as the Ras/cAMP/PKA pathway, calmodulin/calcineurin pathway (CaM/CaL), and mitogen-activated protein kinase (MAPK) signaling pathways [19,20]. However, the most studied ones are described below. The ATP-binding cassette (ABC) and the major facilitator superfamily (MFS) transporters are responsible for lowering the accumulation of azoles inside the yeast cell by translocating compounds actively across the cell membrane [21]. Overexpression of genes encoding drug transporters, e.g., Cdr1/2-ABC and Mdr1/Flu1-MFS, among resistant isolates of Candida species is predominantly due to gain-of-function (GOF) mutations in genes encoding zinc cluster transcription factors, such as TAC1 (transcriptional activator of CDR genes) and MRR1 (<u>multidrug resistance regulator</u>). For instance, GOFs in TAC1 (T225A, R693K, A736V, H741, N972D, G980E, N997D) and MRR1 (I283R, R479K, G583R, V854A, K873N), lead to overexpression of CDR1 and MDR1 in C. albicans and C. parapsilosis, respectively [22,23]. Overexpression of ERG11, the gene encoding lanosterol 14 α -demethylase, the azole target, contributes directly to resistance as the increased abundance of the target requires higher drug doses for inhibition. Activating mutations in the gene encoding the transcription factor Upc2, which up-regulates most ergosterol biosynthesis genes, and the formation of an isochromosome with two copies of the left arm of chromosome 5 [i(5L)], or by duplication of the whole chromosome, on which ERG11 resides, are responsible for ERG11 overexpression [24]. Furthermore, point mutations in the ERG11 alter the 3D conformation of Erg11 and

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

reduce its affinity for FLC. Some of the most frequent amino acid substitutions reported are Y132F and K143R substitutions, described in C. albicans, C. parapsilosis and C. auris [15,25,26]. Although Candida isolates from individual institutions may not be representative of the data of a country, such studies can provide a useful baseline snapshot of species distribution and antifungal susceptibility for candidemia in resource-limited settings [10]. In Colombia, there is a lack of data available about antifungal resistance and its molecular mechanisms in Candida spp. Therefore, this study aimed to investigate the prevalence of resistance and to describe the mechanisms behind FLC-resistance in a collection of bloodstream isolates. Materials and methods Study design The study was a single-center retrospective analysis. One hundred twenty-three bloodstream isolates of *Candida* spp. obtained from hospitalized patients (2016-2020) of the San Ignacio Hospital in Bogota, Colombia were included. Prior to storage at -80 °C, yeast from blood cultures submitted for routine work-up to the Clinical Microbiology Laboratory were primarily identified using MicroScan (MicroScan WalkAway-96 Plus, Siemens, Deerfield, IL, USA) or VITEK 2 system (bioMérieux, Marcy-l'Etoile, France), and further characterized (this study) using the MALDI-TOF Biotyper system (Bruker Daltonik, Bremen, Germany). 2.2 MALDI-TOF MS Isolates were streaked from a glycerol stock onto Sabouraud dextrose agar (SDA) and grown for 24–36 h at 35 °C. Protein extraction was performed using formic acid/ethanol method, according to the Bruker Daltonics' protocol. The protein mass spectra were analysed using the Flex Control software and the MALDI Biotyper version 3.1 7311 reference spectra (main spectra) (Bruker Daltonics, Bremen, Germany). MALDI-TOF MS results were obtained

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

according to the manufacturer's technical specifications, as follows: correct genus and species identification (≥ 2.0), correct genus identification (1.7–2.0), and no reliable identification (<1.7). All clinical isolates had a score above 2.0 [27]. 2.3 Antifungal susceptibility testing Susceptibility to FLC (Sigma-Aldrich, St. Louis, MO, USA) was conducted using the Clinical and Laboratory Standards Institute broth microdilution method (CLSI-BMD), following the M27-A3 document [28]. Briefly, isolates were suspended in 1 mL phosphate buffered saline (PBS) and diluted in liquid RPMI 1640 medium to 10³ cells/mL in a 96-well plate, containing a gradient of two-fold dilutions per step of antifungal, with the first well containing no drug. Minimum inhibitory concentrations (MICs) were visually, and densitometry determined as the lowest concentration of drug that caused a significant diminution (MIC/2 or >50%) compared with that of the drug-free growth control after 24 h of incubation. Quality control was ensured by testing the CLSI-recommended strains C. parapsilosis ATCC 22019 and C. krusei ATCC 6258. For NACS isolates the CLSI breakpoints were applied (resistance to FLC was set at C. albicans, C. tropicalis, and C. parapsilosis ≥8µg/mL and C. glabrata ≥64µg/mL) [29]. In the case of C. auris, the FLC breakpoint recommended by the US Centers for Disease Control and Prevention (CDC) was used (≥32 µg/mL) [30]. The MIC data obtained under routine conditions for amphotericin B (AMB), caspofungin (CAS), itraconazole (ITC), and voriconazole (VRC) by Etest® (bioMérieux, Marcy-l'Étoile, France) and VITEK®2 (bioMérieux) are presented in **Table S1**. Sequencing analysis of Erg11, Tac1 and Mrr1-encoding genes All isolates displaying resistance to FLC, and one susceptible isolate of each species were subjected to a single-tube PCR method to amplify and sequence the coding region of the ERG11, TAC1 or MRR1 genes (both strands) using the primers indicated in **Table S2**. The

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

PCR products were purified and sequenced using a SeqStudio genetic analyzer capillary sequencer (Applied Biosystems). The sequencing results were analyzed by BLAST and compared with the published GenBank sequences: C. albicans AY856352.1 (ERG11), DQ393587 (TAC1), and C. parapsilosis GQ302972 (ERG11), HE605205 (MRR1). For C. auris, sequences download from the Candida genome database (candidagenome.org) were used, i.e., B9J08 001448 (C. auris B8441, ERG11) and B9J08 004820 (TAC1b). All sequences (FLC-susceptible and resistant clinical isolates plus reference strains) were aligned, and the dataset was used to construct a Neighbor-Joining phylogenetic tree using Maximum Composite Likelihood settings by using Molecular Evolutionary Genetics Analysis Version 11 (MEGA11) [31,32]. Codon positions included were 1st + 2nd + 3rd + Noncoding. All positions containing gaps and missing data were eliminated. Evaluation of branch support was performed by Bootstrap statistical analysis with 1000 replicates [31]. Analysis of rhodamine 6G efflux ABC transporter-mediated efflux was determined using rhodamine 6G (Sigma-Aldrich, USA) as previously described [33]. The fluorescence of the released R6G was measured at 530 nm, with an emission at 560 nm in an automated plate reader (Model 550 Microplate Reader Bio-Rad, Milan, Italy). Measurements were made before (basal) and after the addition of 20 mM glucose. Using a R6G calibration curve, the fluorescence intensity was converted into concentration. **Statistics** Experiments were performed in triplicate, in three independent experimental sets. The results were analyzed statistically by the Analysis of Variance One-Way ANOVA. All the analyses were performed using GraphPad Prism version 9 software. In all analyses, p values of 0.05 or less were considered statistically significant.

Results

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

Identification and Antifungal susceptibility testing of clinical isolates The Candida species distribution from the 123 blood samples was as follows: C. albicans, 46 (37.4%); C. tropicalis, 33 (26.8%); C. parapsilosis, 24 (19.5%); C. auris, 10 (8.1%); C. glabrata, 5 (4.1%); C. krusei, 3 (2.4%); and C. lusitaniae, 2 (1.6%). Although C. albicans was the most prevalent species, accounting for 37.4%, the NACS group comprised 62.6% of the isolates identified. Concerning susceptibility, when applying the CLSI and CDC breakpoints, 22 out of 123 (18%) isolates displayed in vitro resistance to FLC, among them, six of C. albicans, six of C. parapsilosis and seven of C. auris (19/23). Moreover, three isolates of C. krusei -as C. krusei is assumed to be intrinsically resistant to FLC-, were not included within the molecular study. In contrast, all isolates of C. tropicalis, C. glabrata, and C. lusitaniae were FLC-susceptible **Figure 1**. The MICs values obtained for FLC are shown in **Table 1**. The MIC₉₀ values (MICs at which ≥90% of strains are inhibited) for the four most frequent species found were: C. albicans 128µg/mL, C. tropicalis 2µg/mL, C. parapsilosis 32µg/mL and C. auris >128µg/mL. As expected, C. auris presented the highest MIC₉₀ values. In addition, the range of FLC MICs was narrower for C. auris and C. glabrata than for the other species. On the other hand, C. tropicalis showed reduced susceptibility to FLC (MIC₉₀= 2µg/mL). Regarding VRC MICs (data obtained by Etest), 10 out of 19 FLC-resistant isolates, excluding C. krusei, were VRC cross-resistant. The highest MICs were observed for C albicans (32 µg/mL) **Table S3.** Detection of mutations in Erg11, Tac1 and Mrr1-encoding genes of 19 FLC-resistant isolates. By comparing the ERG11 coding region of C. albicans (CAAL, A-F), C. auris (CAAU, A-G)

and C. parapsilosis (CAPA, A-F) FLC-resistant isolates with that of our FLC-susceptible and

the published wild-type sequences, we identified 20, 16, and three mutations, respectively. As expected, some silent mutations that do not change the protein sequence were identified (data not shown). The remaining ERG11 mutations which resulted in amino acid changes are shown in **Figure 2, Table S4**. Among the nonsense mutations (*C. albicans* 6; *C. auris* 5; and C. parapsilosis 2), three amino acid substitutions related with FLC-resistance (T220L, Y132F, K143R) were found from which Y132F was the most detected. Additionally, five amino acid substitutions previously described in FLC-susceptible isolates were observed (D116E, K128T, K177R, N335S, E343D). To the best of our knowledge, four amino acid substitutions (K22E, Q38T, F72V, Q77S) have not been previously reported. Overall, eight of the 19 FLC-resistant isolates did not have resistance-associated substitutions. On the other hand, except for isolate CAAL-A, which harbored a K128T substitution in only one ERG11 allele, other isolates were homozygous for mutations in the ERG11 allele. In the phylogenetic relationship among FLC-resistant, susceptible isolates and reference strains, a cluster of isolates carrying the substitutions Y132F in C. auris was observed, as well as in the FLC-resistant C. albicans isolates harboring K128T substitution. In addition, susceptible and resistant isolates without resistance-associated ERG11 mutations (i.e., T220L, Y132F) from these species were clustered Figure 2A-B. Concerning TAC1 (C. albicans and C. auris) and MRR1 (C. parapsilosis) genes, no mutations previously associated with FLC-resistance were found. However, 17 Tac1 (*C. albicans*, n=7; C. auris, n=10) and Mrr1 (C. parapsilosis, n=1) amino acid substitutions previously described in FLC-susceptible isolates were found. Additionally, there were 37 unreported substitutions in Tac1 (C. albicans, n=7; C. auris, n=26) and Mrr1 (C. parapsilosis, n=4) Figure 2, Table **S3.**

Efflux Pumps activity

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

To gain further insights into the mechanisms of azole resistance in the clinical isolates the activity of efflux pumps was evaluated using rhodamine 6G, which uses the same membrane ABC transporters (Cdr1p and Cdr2p) as FLC in Candida. Among the 19 FLC-resistant isolates, eight of them showed significant active efflux of rhodamine-6G after addition of glucose: two of them belonging to C. albicans (CAAL-C and CAAL-E); four to C. auris (CAAU-A, CAAU-B, CAAU-C and CAAU-G) and two to C. parapsilosis (CAPA-C, CAPA-F) Figure 3, Figure 1S. Interestingly, no amino acid substitutions associated with FLCresistance were identified in both C. albicans isolates (CAAL-C, 128µg/mL), (CAAL-D, 128µg/mL). Regarding the remaining isolates that showed efflux pump activity, C. auris (CAAU-A, CAAU-B, CAAU-C, CAAU-G) and C. parapsilosis (CAPA-C, CAPA-F) harbored the Y132F substitution. In summary, 11/19 resistant isolates harbored an amino acid substitution associated with FLC-resistance; 8/19 displayed efflux pumps activity; 6/19 had both amino acid substitutions and efflux pump activity; and 3/19 isolates did not exhibit any of the mechanisms that could explain their resistant phenotype **Figure 4**. **Discussion** Our study agrees that the three species most found in bloodstream infections in Latin America are C. albicans, C. tropicalis and C. parapsilosis [34,35]. However, the percentage of C. tropicalis (26.8% vs. 13.6%) and C. parapsilosis (19.5% vs. 13.6%) found differs from that observed in the first decade of the 2000s in Colombia [36]. Similar results were found for species distribution in studies conducted at the same hospital between 2003 and 2014, however, we observed a slight increase in NACS (62,6% vs. 58%) and the presence of C. auris, which was not described in these studies [37,38]. In the region, a study that evaluated susceptibility of the species identified in Colombia, Ecuador, and Venezuela, found a percentage of resistance to FLC of 6.8% [39]. This shows that there is an important change in

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

the distribution and rate of resistance, which in our study reached 18%. Nevertheless, the majority of *C. albicans* isolates were azole susceptible, thus the observed resistance percentage is mainly attributed to the presence of *C. auris*, which agrees with previous studies [35,40]. Furthermore, it is noteworthy that 25% of the *C. parapsilosis* isolates were resistant to FLC, which confirms the increase of resistance in this species **Figure 5** [41]. High azole resistance rates have been reported for this species in other single-center studies conducted in Brazil (67.9%), Italy (33%), France (9.2%), Mexico (54%), Saudi Arabia (33%), Spain (13.6%), South Africa (78%) or Turkey (26.4%) [11,13,42–46]. Overall, the global data indicate that C. albicans remains the predominant species identified in Candida infections. Herein, C. albicans was the most predominant species, nevertheless, NACS accounted for a high proportion (62.6%). Although reported resistance rates vary from study to study, the surveillance data collected suggest that azole resistance rates for C. albicans remain low [35,47]. Remarkably, in this study, the percentage of FLC resistance in C. albicans was 15%, which is relatively high. However, C. albicans infections in the bloodstream pose a considerable threat in immunocompromised populations and the associated high mortality remains a major problem in the clinical setting. Therefore, C. albicans should not be overlooked as a serious public health threat. The acquisition of azole resistance is a serious concern given the limited number of molecules available for the treatment of IFIs. Moreover, this is much more worrying in resource-limited regions where FLC is the only available therapy [48]. As previously described, azole resistance is mainly conferred by mutations in the ERG11 gene and by the activity of efflux pumps. The ERG11 gene is highly polymorphic and more than 140 amino acid substitutions have been reported, indicating that this protein is very permissive to conformational changes.

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

It does not seem to be a clonal spread (**Table S3**).

Most substitutions occur in three amino acid hotspot regions (105-165, 266-287 and 405-488), although mutations outside these regions can also be found [49,50]. In the present study, 11 of the 19 FLC-resistant isolates harbored mutations which have been previously described in resistant isolates (T220L, Y132F, K143R) [11,51]. Notably, the T220L substitution was observed in one C. albicans isolate. In C. auris, five isolates carried the Y132F, and in the case of *C. parapsilosis* four isolates harbored the Y132F and one the K143R substitution. The substitution of lysine for threonine at position 128 (K128T) was found in CAAL-A, CAAL-B and CAAL-D isolates, which is consistent with the findings of Cernicka et al., and Peron et al., who identified this amino acid substitution in FLC-resistant strains [52,53]. However, several studies refute this association because K128T substitution has been found in multiple FLC-susceptible isolates, hence, in this study, we do not consider it as a mutation associated with resistance [25,54]. Nevertheless, it might influence translation efficiency, leading to alterations in protein production as it occurs with nearby mutations such as G129R and Y132F [55]. According to Chow and coworkers, mutations contributing to FLC resistance are cladespecific in C. auris, being Y132F and K143R the most predominant in clade I, F126L in clade III, and Y132F in clade IV. However, Y132F in Erg11 is the most prevalent one [26]. As described for isolates of clade IV (South America), we found only one mutation: Y132F. Concerning C. parapsilosis, high prevalence of the Y132F substitution was also noted in previous studies [56,57]. In addition, the latter suggested that isolates harbouring this mutation may have a higher propensity to cause clonal transmission and to persist in nosocomial settings [58]. Regarding our isolates, the Y132F substitution was detected in four out of six C. parapsilosis isolates. However, considering the dates of collection of the isolates,

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

Although previous studies indicate that the Mrr1 substitutions I283R, R479K, G583R, A854V, K873N and L986P are associated with FLC and/or VRC resistance, none of our isolates harbored them [59]. Similar to Tac1, residues located near the C terminus (760, 761, 803, 956, and 966) might contribute to azole resistance [47]. This study also illustrates that acquired azole resistance commonly relies on combined molecular mechanisms in clinical isolates. In addition to amino acid substitutions in Erg11, six of the 19 isolates also displayed active efflux activity. Interestingly, in two isolates lacking resistance-related mutations, efflux pumps activity was observed. Considering that efflux pumps play a key role in azole resistance, this might be the explanation for the observed phenotype. However, a further study evaluating the expression of all genes involved in efflux pump activity is required. Regarding the isolates in which no mechanism for resistance was found, namely CAAL-A-E, CAAU-D, CAAU-E and CAPA-A, six novel Tac1 or Mrr1 substitutions (G52R, V366del, F682T, F683L, T695S and P229A) were identified in three of the five isolates. Moreover, four novel Erg11 substitutions (K22E, Q38T, F72V, Q77S) in the FLC resistant C. albicans (CAAL-B, CAAL-C) and *C. auris* (CAAU-B) were found. The putative role of these substitutions remains to be investigated. In isolates CAAL-A-D and CAAU-E, a different mechanism to those evaluated here should confer resistance; further analysis is ongoing. Our study has some limitations. For instance, the AST data obtained for antifungals other than FLC are not complete and were not performed by BMD. The molecular basis of FLC resistance was investigated only by analysis of the ERG11, TAC1, and MRR1 genes, while other mechanisms conferring resistance, such as sterol composition and gene expression, were not investigated due to lack of funds. Finally, the clinical description of the patients was missing and will be reported alongside other patients infected by Candida antifungal resistant strains elsewhere.

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

Recently, the WHO published a list of priority pathogenic fungi (FPP) which includes C. albicans, C auris (Critical group), and C. parapsilosis (high group). The WHO describes that to overcome the lack of knowledge on infections caused by these fungi, more data and evidence on fungal infections and antifungal resistance to inform and improve response to FPP is needed [60]. Although our study does not have a large number of isolates and does not include other healthcare institutions, we provide evidence of endemic isolates harboring resistance mutations to one of the most used molecules in the hospital setting. In conclusion, we describe the presence of *Candida* spp isolates harboring Erg11 FLC resistant-related substitutions (Y132F, K143R and T220L) in patients admitted to a Colombian hospital. Although FLC-resistance rates differ significantly between countries and individual health facilities, the resistance rate in our study is relatively high, emphasizing the need for active surveillance to prevent further expansion of FLC-resistant Candida spp isolates in the clinical setting. **Funding** The research office of Hospital Universitario San Ignacio and the Vice-Rectory of research at the Pontificia Universidad Javeriana in Bogotá, Colombia, supported the research (grants no.2014-52 and 20454). Ethics approval and consent to participate The research and ethics committee of the Hospital Universitario San Ignacio (HUSI) approved this study (no. FM-CIE-8053-14). All patients are anonymized and only the code of isolates was transferred for this investigation. Therefore, no informed consent was required. **Competing interests** The authors declare that they have no competing interests. **Author contributions:**

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

AP carried out the experiments; Y.V-C contributed to the development of efflux pumps protocol; AC-G, and AP analyzed the data; AC-G wrote the main manuscript; AP, SV-B, BA, and CP-G review and editing; and CP-G conceived the experiments and managed the resources. All authors have read and agreed to the published version of the manuscript. References 1 Koehler P, Stecher M, Cornely OA et al. Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis. Clin Microbiol Infect 2019; 25: 1200–1212. 2 Pappas PG, Lionakis MS, Arendrup MC, Ostrosky-Zeichner L, Kullberg BJ. Invasive candidiasis. Nat Rev Dis Prim 2018; 4: 1-20. 3 Pemán J, Cantón E, Gobernado M. Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005; 24: 23–30. 4 Lamoth F, Lockhart SR, Berkow EL, Calandra T. Changes in the epidemiological landscape of invasive candidiasis. J Antimicrob Chemother 2018; 73: i4–i13. 5 Chen J, Tian S, Han X et al. Is the superbug fungus really so scary? A systematic review and meta-analysis of global epidemiology and mortality of Candida auris. BMC Infect Dis 2020; 20: 827. 6 Carradori S, Ammazzalorso A, De Filippis B et al. Azole-Based Compounds That Are Active against Candida Biofilm: In Vitro, In Vivo and In Silico Studies. Antibiot 2022, Vol 11, Page 1375 2022; 11: 1375. 7 Sheehan DJ, Hitchcock CA, Sibley CM. Current and emerging azole antifungal agents. Clin Microbiol Rev 1999; **12**: 40–79. 8 Morio F, Jensen RH, Le Pape P, Arendrup MC. Molecular basis of antifungal drug

366 resistance in yeasts. Int J Antimicrob Agents 2017; **50**: 599–606. 367 Carolus H, Pierson S, Muñoz JF et al. Genome-wide analysis of experimentally 9 368 evolved candida auris reveals multiple novel mechanisms of multidrug resistance. 369 MBio 2021; 12. doi:10.1128/mBio.03333-20. 370 10 Govender NP, group on behalf of the T-SA, Patel J et al. Emergence of azole-resistant 371 Candida parapsilosis causing bloodstream infection: results from laboratory-based 372 sentinel surveillance in South Africa. J Antimicrob Chemother 2016; 71: 1994–2004. 373 11 Arastehfar A, Daneshnia F, Hilmioglu-Polat S et al. First report of candidemia clonal 374 outbreak caused by emerging fluconazole-resistant candida parapsilosis isolates 375 harboring Y132F and/or Y132F+K143R in Turkey. Antimicrob Agents Chemother 2020; **64**. doi:10.1128/AAC.01001-20/SUPPL_FILE/AAC.01001-20-S0001.PDF. 376 377 12 Castanheira M, Deshpande LM, Messer SA, Rhomberg PR, Pfaller MA. Analysis of 378 global antifungal surveillance results reveals predominance of Erg11 Y132F alteration 379 among azole-resistant Candida parapsilosis and Candida tropicalis and country-specific 380 isolate dissemination. Int J Antimicrob Agents 2020; 55. 381 doi:10.1016/J.IJANTIMICAG.2019.09.003. 382 Díaz-García J, Gómez A, Alcalá L et al. Evidence of Fluconazole-Resistant Candida 13 383 parapsilosis Genotypes Spreading across Hospitals Located in Madrid, Spain and 384 Harboring the Y132F ERG11p Substitution. Antimicrob Agents Chemother 2022; 66. 385 doi:10.1128/AAC.00710-22. 386 Asadzadeh M, Ahmad S, Al-Sweih N, Khan Z. Epidemiology and Molecular Basis of 14 387 Resistance to Fluconazole Among Clinical Candida parapsilosis Isolates in Kuwait. 388 Microb Drug Resist 2017; 23: 966–972.

389	15	Berkow EL, Manigaba K, Parker JE, Barker KS, Kelly SL, Rogers PD. Multidrug
390		Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal
391		Resistance in Candida parapsilosis. Antimicrob Agents Chemother 2015; 59 : 5942–
392		5950.
393	16	Ceballos-Garzon A, Wintaco-Martínez LM, Velez N et al. Persistence of clonal azole-
394		resistant isolates of Candida albicans from a patient with chronic mucocutaneous
395		candidiasis in Colombia. J Glob Infect Dis 2020; 12: 16–20.
396	17	Costa-De-Oliveira S, Rodrigues AG. Candida albicans Antifungal Resistance and
397		Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.
398		microorganisms 2020; 8 : 1–19.
399	18	Rojas AE, Pérez JE, Hernández JS et al. Análisis cuantitativo de la expresión de genes
400		de resistencia a fluconazol en cepas de Candida albicans aisladas al ingreso de adultos
401		mayores a una unidad de cuidados intensivos de Manizales, Colombia. Biomédica
402		2020; 40 : 153–165.
403	19	Pristov KE, Ghannoum MA. Resistance of Candida to azoles and echinocandins
404		worldwide. Clin Microbiol Infect 2019; 25: 792–798.
405	20	Shapiro RS, Robbins N, Cowen LE. Regulatory Circuitry Governing Fungal
406		Development, Drug Resistance, and Disease. Microbiol Mol Biol Rev 2011; 75: 213-
407		267.
408	21	Costa-de-oliveira S, Rodrigues AG. Candida albicans antifungal resistance and
409		tolerance in bloodstream infections: The triad yeast-host-antifungal. Microorganisms.
410		2020; 8 . doi:10.3390/microorganisms8020154.
411	22	Coste A, Turner V, Ischer F et al. A mutation in Tac1p, a transcription factor regulating

412 CDR1 and CDR2, is coupled with loss of heterozygosity at chromosome 5 to mediate 413 antifungal resistance in Candida albicans. Genetics 2006; 4: 2139–56. 414 23 Liu J-Y, Wei B, Wang Y et al. The H741D mutation in Tac1p contributes to the 415 upregulation of CDR1 and CDR2 expression in Candida albicans. Brazilian J 416 Microbiol 2020; **51**: 1553–1561. 417 24 Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. Mechanisms of Antifungal 418 Drug Resistance. Cold Spring Harb Perspect Med 2014; 5: 019752. 419 25 Flowers SA, Colón B, Whaley SG, Schuler MA, David Rogers P. Contribution of 420 clinically derived mutations in ERG11 to azole resistance in Candida albicans. 421 Antimicrob Agents Chemother 2015; **59**: 450–460. 422 26 Chow NA, Muñoz JF, Gade L et al. Tracing the evolutionary history and global 423 expansion of candida auris using population genomic analyses. MBio 2020; 11. 424 doi:10.1128/mBio.03364-19. 425 27 Ceballos-Garzon A, Amado D, Vélez N, Jiménez-A MJ, Rodríguez C, Parra-Giraldo 426 CM. Development and Validation of an in-House Library of Colombian Candida auris 427 Strains with MALDI-TOF MS to Improve Yeast Identification. *J Fungi* 2020; **6**: 1–9. 428 28 CLSI. M27-A3 Reference Method for Broth Dilution Antifungal Susceptibility Testing 429 of Yeasts—Third Edition. Clin Lab Stand Inst 2008; 37: 1-2. 430 29 CLSI. M60ed1e: Performance Standards for Antifungal Susceptibility Testing of 431 Yeasts, 2nd ed.; Clinical and Laboratory Standards Institute: Wayne, PA, USA. 2018. 432 30 CDC. Centers for Disease Control and Prevention. Antifungal Susceptibility Testing 433 and Interpretation to Laboratorians and Health Professionals. Access date: 07-07-21. 434 https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html.

435 2020.https://www.cdc.gov/fungal/candida-auris/ (accessed 10 Jul2021). 436 31 Tamura K, Stecher G, Kumar S. MEGA11: Molecular Evolutionary Genetics Analysis 437 Version 11. Mol Biol Evol 2021; 38: 3022–3027. 438 32 Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing 439 phylogenetic trees. Mol Biol Evol 1987; 4: 406–425. 440 33 Gbelska Y, Toth Hervay N, Dzugasova V, Konecna A. Measurement of Energy-441 dependent Rhodamine 6G Efflux in Yeast Species. BIO-PROTOCOL 2017; 7: 1–5. 442 Nucci M, Queiroz-Telles F, Alvarado-Matute T et al. Epidemiology of Candidemia in 34 443 Latin America: A Laboratory-Based Survey. *PLoS One* 2013; **8**: e59373. 444 35 Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN. Twenty years of the 445 SENTRY Antifungal Surveillance Program: Results for Candida species from 1997-446 2016. Open Forum Infect Dis 2019; **6**: S79–S94. 447 Cortés JA, Reyes P, Gómez C, Buitrago G, Leal AL. Fungal bloodstream infections in 36 448 tertiary care hospitals in Colombia. Rev Iberoam Micol 2011; 28: 74–78. 449 Torres D NA, Álvarez M CA, Rondón S MA. Evaluación mediante tres técnicas de 37 450 susceptibilidad a fluconazol en especies de Candida aisladas en pacientes con 451 infecciones invasoras: Bogotá - Colombia. Rev Chil infectología 2009; 26: 135–143. 452 38 Barahona-Correa J, Calvo-Valderrama M, Romero-Alvernia D et al. Epidemiology of 453 Candidemia at a University Hospital in Colombia. *Univ Medica* 2019; **60**: 1–9. 454 39 De bedout C, Ayabaca J, Vega R et al. Evaluation of Candida species' susceptibility to 455 fluconazole with the disk diffusion method]. *Biomedica* 2003; **1**: 31–37. 456 40 Sathi FA, Paul SK, Ahmed S et al. Prevalence and Antifungal Susceptibility of

457 Clinically Relevant Candida Species, Identification of Candida auris and Kodamaea 458 ohmeri in Bangladesh. Trop Med Infect Dis 2022; 7: 211. 459 41 Escribano P, Guinea J. Fluconazole-resistant Candida parapsilosis: A new emerging 460 threat in the fungi arena. Front Fungal Biol 2022; 0: 69. 461 42 Fekkar A, Blaize M, Bouglé A et al. Hospital outbreak of fluconazole-resistant candida 462 parapsilosis: Arguments for clonal transmission and long-term persistence. Antimicrob 463 Agents Chemother 2021; 65. doi:10.1128/AAC.02036-20/SUPPL_FILE/AAC.02036-464 20-S000S1.PDF. 465 43 Mesini A, Mikulska M, Giacobbe DR et al. Changing epidemiology of candidaemia: 466 Increase in fluconazole-resistant Candida parapsilosis. *Mycoses* 2020; **63**: 361–368. 467 44 Corzo-Leon DE, Peacock M, Rodriguez-Zulueta P, Salazar-Tamayo GJ, MacCallum 468 DM. General hospital outbreak of invasive candidiasis due to azole-resistant Candida 469 parapsilosis associated with an Erg11 Y132F mutation. Med Mycol 2021; **59**: 664–671. 470 45 Thomaz DY, de Almeida JN, Sejas ONE et al. Environmental Clonal Spread of Azole-471 Resistant Candida parapsilosis with Erg11-Y132F Mutation Causing a Large 472 Candidemia Outbreak in a Brazilian Cancer Referral Center. J Fungi 2021, Vol 7, Page 473 *259* 2021; **7**: 259. 474 46 Magobo RE, Lockhart SR, Govender NP. Fluconazole-resistant Candida parapsilosis 475 strains with a Y132F substitution in the ERG11 gene causing invasive infections in a 476 neonatal unit, South Africa. Mycoses 2020; 63: 471–477. 477 47 Nishimoto AT, Sharma C, Rogers PD. Molecular and genetic basis of azole antifungal 478 resistance in the opportunistic pathogenic fungus Candida albicans. J Antimicrob 479 Chemother 2020; **75**: 257–270.

480 48 Kneale M, Bartholomew JS, Davies E, Denning DW. Global access to antifungal 481 therapy and its variable cost. J Antimicrob Chemother 2016; 71: 3599–3606. 482 49 Oliveira-Carvalho V, Del Negro GMB. Is the S405F mutation in Candida albicans 483 ERG11 gene sufficient to confer resistance to fluconazole? J Mycol Med 2014; 24: 484 241-242. 485 50 Debnath S, Addya S. Structural basis for heterogeneous phenotype of ERG11 486 dependent Azole resistance in C. albicans clinical isolates. Springerplus 2014; 3. 487 doi:10.1186/2193-1801-3-660. 488 51 Healey KR, Kordalewska M, Ortigosa CJ et al. Limited ERG11 mutations identified in 489 isolates of candida auris directly contribute to reduced azole susceptibility. Antimicrob 490 Agents Chemother 2018; 62. doi:10.1128/AAC.01427-18. 491 52 Cernicka J, Subik J. Resistance mechanisms in fluconazole-resistant Candida albicans 492 isolates from vaginal candidiasis. *Int J Antimicrob Agents* 2006; **27**: 403–408. 493 53 Peron IH, Reichert-Lima F, Busso-Lopes AF et al. Resistance surveillance in Candida 494 albicans: A five-year antifungal susceptibility evaluation in a Brazilian University 495 Hospital. *PLoS One* 2016; **11**. doi:10.1371/journal.pone.0158126. 496 54 Morio F, Loge C, Besse B, Hennequin C, Le Pape P. Screening for amino acid 497 substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-498 resistant clinical isolates: new substitutions and a review of the literature. Diagn 499 Microbiol Infect Dis 2010; 66: 373-384. 500 55 Kumar A, Nair R, Kumar M et al. Assessment of antifungal resistance and associated 501 molecular mechanism in Candida albicans isolates from different cohorts of patients in 502 North Indian state of Haryana. Folia Microbiol 2020 654 2020; 65: 747–754.

Grossman NT, Pham CD, Cleveland AA, Lockhart SR. Molecular mechanisms of fluconazole resistance in Candida parapsilosis isolates from a U.S. surveillance system. Antimicrob Agents Chemother 2015; **59**: 1030–7. Choi YJ, Kim YJ, Yong D et al. Fluconazole-Resistant Candida parapsilosis Bloodstream Isolates with Y132F Mutation in ERG11 Gene, South Korea. Emerg Infect Dis 2018; 24: 1768. Thomaz DY, De Almeida JN, Lima GME et al. An azole-resistant candida parapsilosis outbreak: Clonal persistence in the intensive care unit of a Brazilian teaching hospital. Front Microbiol 2018; 9: 2997. Branco J, Silva AP, Silva RM et al. Fluconazole and voriconazole resistance in Candida parapsilosis is conferred by gain-of-function mutations in MRR1 transcription factor gene. Antimicrob Agents Chemother 2015; 59. doi:10.1128/AAC.00842-15. World Health Organization (WHO). Fungal priority pathogens list to guide research, development and public health action. 2022https://www.who.int/publications/i/item/9789240060241 (accessed 3 Nov2022).




Figure 1. Species distribution and overall fluconazole susceptibility results.

A) Distribution of the 123 species identified. B) Percentage of fluconazole resistance. The number of isolates is indicated inside the bars. Susceptible (S) isolates are depicted in blue and resistant (R) isolates in red.




Figure 2. Phylogenetic tree and amino acid substitutions found in fluconazole-resistant isolates of **A**) *C. albicans* (CAAL), **B**) *C. auris* (CAAU) and **C**) *C. parapsilosis* (CAPA). aa., amino acids. FLC: fluconazole; MIC: minimal inhibitory concentration. CA-S., *Candida* FLC-susceptible. Inside the colored squares, the number of substitutions found is indicated.




Figure 3. Rhodamine 6G (R6G) efflux over time among fluconazole-resistant isolates. Colored lines indicate the concentration of R6G released after the addition of 20 mM glucose (GLU). Data are means \pm SD from three experiments. *p < 0.05, **p < 0.01, ***p < 0.001. ****p < 0.0001. FLC: fluconazole; MIC: minimal inhibitory concentration.

558

559

560

561

562

563




Figure 4. Schematic representation of the results obtained in this study for the 19 FLCresistant isolates. In purple C. albicans, light blue C. parapsilosis and yellow C. auris isolates with their respective MICs against FLC. In red font, the mutations found. The green stars indicate isolates with significant efflux pump activity. The size of the circle reflects the number of mutations, those not associated with FLC resistance (blue) and the new mutations (light green).




Figure 5. Countries reporting Erg11 substitutions in azole-resistant C. parapsilosis.

Table 1. Antifungal activity of fluconazole drug against *Candida* spp (n = 123) performed by CLSI.

MIC₅₀ and MIC₉₀ values (MICs at which ≥50% and ≥90% of the strains are inhibited, respectively) are depicted in bold and underlined,

Species	D	Number (and cumulative percentage) of C <i>andida</i> spp strains with MIC μg/mL																-	D	
	Drug	≤0.015	0.03	0.06	0.125	0.25	0.50	1	2	4		8	16	32	2	64	128	>128	Total	Range
C. albicans	FLC	4 (9)	1 (11)		1 (13)	19 (54)	9 (74)	3 (80)	1 (83)	2 (87)							4 (96)	2 (100)	46	≤0.015- >128
C. auris	FLC								1 (10)		2	(30)				2 (50)		<u>5 (100)</u>	10	2->128
C. glabrata	FLC							1 (20)	1 (40)	2 (80)	<u>1</u>	(100)							5	1-8.
C. krusei	FLC										1	(33)	<u>2</u>	(100)					3	≤0.015-4
C. lusitaniae	FLC						_		<u>2 (100)</u>										2	2
C. parapsilosis	FLC	2 (8)			1 (13)		3 (25)	5 (46)	3 (58)	4 (75)			1 (79)	<u>3</u>	<u>(92)</u>	2 (100)			24	≤0.015-6
C. tropicalis	FLC			4 (12)		6 (30)	10 (61)	3 (70)	<u>8 (94)</u>	2 (100)									33	0.06-4
Overall																			123	

respectively.